Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**PCV-LITE + LVA** is a novel, low-dose pneumococcal conjugate vaccine formulation composed of one-fifth the standard dose of the 20-valent pneumococcal conjugate vaccine (PCV20) combined with 1 mg of LiteVax Adjuvant (LVA). It is designed to enhance the immunogenicity of low-dose PCV20 using the LVA immunoadjuvant. The vaccine is delivered as a single intramuscular injection, and its primary objective is to elicit a strong immune response against *Streptococcus pneumoniae* using less antigen through adjuvantation. The product is in Phase 1 clinical development to assess its safety, tolerability, and immunogenicity as compared to full-dose and non-adjuvanted controls. PCV-LITE + LVA is being developed by LiteVax, as indicated by ongoing clinical trials in healthy adults[1][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PCV-LITE + LVA.